Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong market demand in the peptide sector [1] Financial Performance - The expected revenue for 泰德医药 is projected to be between RMB 5.55 billion and RMB 5.85 billion, representing a year-on-year increase of approximately 25.5% to 32.3% [1] - The anticipated profit is estimated to be between RMB 2 billion and RMB 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Strategic Factors - Revenue growth is attributed to the successful execution of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company highlights its industry-leading project delivery timeliness and excellent project execution track record as key contributors to its performance [1] - There is a strong and growing demand from key clients for the company's services, driven by advancements in its research and development pipeline and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [1]